CELG Shares Outstanding History
Below is a table of the CELG shares outstanding history going back to 2/11/2010:

Date CELG Shares Outstanding
2/11/2010919.46M
4/23/2010921.73M
7/23/2010918.91M
10/26/2010941.28M
2/18/2011929.80M
4/27/2011925.60M
10/25/2011887.86M
2/16/2012877.62M
4/25/2012881.00M
7/23/2012862.85M
10/19/2012845.97M
12/31/2012837.49M
4/23/2013834.24M
7/23/2013822.55M
10/22/2013824.14M
2/7/2014812.04M
4/21/2014800.83M
6/26/2014800.83M
7/22/2014799.51M
10/21/2014798.70M
2/12/2015800.59M
4/24/2015793.14M
7/24/2015790.54M
10/30/2015785.65M
2/5/2016781.66M
4/26/2016774.60M
7/22/2016775.11M
10/21/2016775.20M
2/3/2017777.97M
4/20/2017780.82M
7/21/2017782.35M
10/23/2017787.32M
2/2/2018752.18M
4/23/2018724.83M
7/23/2018703.36M
10/22/2018699.25M
2/21/2019702.16M
2/27/2019702.36M
4/22/2019705.26M
7/26/2019708.74M
10/29/2019711.71M

Also see: CELG Market Cap History
and CELG YTD Return
CELG Historical Shares Outstanding:
-2.60% CAGR
CELG Historical Shares Outstanding: +-2.60% CAGR

Mouse over chart for data details
2/11/2010 ...10/29/2019
Celgene is a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Co.'s primary commercial stage products include: REVLIMID®, an oral immunomodulatory drug; POMALYST®/IMNOVID®, a proprietary, small molecule; OTEZLA®, an oral small-molecule inhibitor of phosphodiesterase 4 for cyclic adenosine monophosphate; ABRAXANE®, a solvent-free chemotherapy product; and VIDAZA®, a pyrimidine nucleoside analog. In addition, Co. provides other product sales and licensing arrangements. We show 41 historical shares outstanding datapoints in our coverage of CELG's shares outstanding history.

Understanding the changing numbers of CELG shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CELG versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CELG by allowing them to research CELG shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for CELG:
CELG SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Celgene (CELG) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CEMI Shares Outstanding History
CERC Shares Outstanding History
CERS Shares Outstanding History
CFMS Shares Outstanding History
CFRX Shares Outstanding History
CGEN Shares Outstanding History
CGIX Shares Outstanding History
CHE Shares Outstanding History
CHFS Shares Outstanding History
CHMA Shares Outstanding History
More Healthcare companies »

 

CELG Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.